Microvascular decompression or neuromodulation in patients with SUNCT and trigeminal neurovascular conflict? by Hassan, S et al.
For Peer Review
 
 
 
 
 
Brief report: Microvascular Decompression or 
Neuromodulation in Patients with SUNCT and Trigeminal 
Neurovascular Conflict? 
 
 
Journal: Cephalalgia 
Manuscript ID CHA-00385-FT-2017.R1 
Manuscript Type: Article for Fast Track Review 
Date Submitted by the Author: n/a 
Complete List of Authors: Hassan, Samih; University College London Hospitals NHS Foundation Trust, 
Victor Horsley department of Neurosurgery 
Lagrata, Susie; 2. Headache Group, UCL Institute of Neurology and 
National Hospital for Neurology and Neurosurgery, Queen Square, London, 
WC1N 3BG, UK, Neurology 
Levy, Andrew; 2. Headache Group, UCL Institute of Neurology and National 
Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 
3BG, UK  , Neurologuy 
Matharu, Manjit; 2. Headache Group, UCL Institute of Neurology and 
National Hospital for Neurology and Neurosurgery, Queen Square, London, 
WC1N 3BG, UK  , Neurology 
Zrinzo, Ludvic; Unit of Functional Neurosurgery, Box 146, Institute of 
Neurology and National Hospital for Neurology and Neurosurgery, 33 
Queen Square, London, WC1N 3BG, UK , Unit of Functional Neurosurgery 
Key Words: Trigeminal nerve 
  
 
 
http://mc.manuscriptcentral.com/cephalalgia
Cephalalgia
For Peer Review
Brief report: Microvascular Decompression or Neuromodulation in 1 
Patients with SUNCT and Trigeminal Neurovascular Conflict? 2 
Authors:  3 
Samih Hassan MBBS MRCS FRCS (SN) 1, Susie Lagrata BSc  2, Andrew Levy 4 
BChD MSc  2, Manjit Matharu PhD FRCP* 2, Ludvic Zrinzo MD PhD FRCS 5 
(Neuro.Surg)* 1,3 6 
 7 
* Both senior authors have equal contribution to the paper 8 
Affiliations: 9 
1. Victor Horsley Department of Neurosurgery, National Hospital for Neurology and 10 
Neurosurgery, Queen Square, London, WC1N 3BG, UK 11 
2. Headache Group, UCL Institute of Neurology and National Hospital for Neurology 12 
and Neurosurgery, Queen Square, London, WC1N 3BG, UK   13 
3. Unit of Functional Neurosurgery, Sobell Department of Motor Neuroscience and 14 
Movement Disorders, UCL Institute of Neurology, University College London, 15 
Queen Square, London, WC1N 3BG, UK 16 
 17 
Corresponding Author:  18 
Ludvic Zrinzo MD PhD FRCSEd (Neuro.Surg) 19 
Unit of Functional Neurosurgery, Box 146, Institute of Neurology and National 20 
Hospital for Neurology and Neurosurgery, 33 Queen Square, London, WC1N 3BG, 21 
UK  22 
Email: l.zrinzo@ucl.ac.uk 23 
Fax: +44 (0) 20 3108 0142  24 
Tel: +44 (0) 20 3108 0026 25 
 26 
 27 
Page 1 of 40
http://mc.manuscriptcentral.com/cephalalgia
Cephalalgia
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
Page 2 
 
ABSTRACT: 1 
Objectives: To assess the relative effectiveness of neuromodulation and trigeminal 2 
microvascular decompression (MVD) in patients with medically intractable short-3 
lasting unilateral neuralgiform headache attacks with conjunctival injection and 4 
tearing (SUNCT). 5 
Methods: Two patients with medically refractory SUNCT underwent MVD following 6 
beneficial but incomplete response to neuromodulation (occipital nerve stimulation 7 
and deep brain stimulation). MRI confirmed neurovascular conflict with the ipsilateral 8 
trigeminal nerve in both patients. 9 
Results: Although neuromodulation provided significant benefit, it did not deliver 10 
complete relief from pain and management required numerous postoperative visits 11 
with adjustment of medication and stimulation parameters. Conversely, MVD was 12 
successful in eliminating symptoms of SUNCT in both patients with no need for 13 
further medical treatment or neuromodulation. 14 
Conclusion: Neuromodulation requires expensive hardware and lifelong follow up 15 
and maintenance. These case reports highlight that microvascular decompression 16 
may be preferable to neuromodulation in the subset of SUNCT patients with 17 
ipsilateral neurovascular conflict.  18 
 19 
 20 
 21 
 22 
 23 
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List of all abbreviations used 1 
CISS   constructive interference in steady state 2 
DBS   deep brain stimulation 3 
ONS   occipital nerve stimulation 4 
MRI   magnetic resonance imaging   5 
MVD   microvascular decompression 6 
SUNA  short-lasting unilateral neuralgiform headache attacks with cranial 7 
autonomic features 8 
SUNCT  short-lasting unilateral neuralgiform headache attacks with conjunctival 9 
injection and tearing 10 
SUNHA short-lasting unilateral neuralgiform headache attacks 11 
TACs   trigeminal autonomic cephalalgias 12 
TN   trigeminal neuralgia 13 
VTA   ventral tegmental area 14 
V2  2nd division of trigeminal nerve 15 
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INTRODUCTION 1 
Short-lasting unilateral neuralgiform headache attacks (SUNHA) are a rare primary 2 
headache disorder characterised by moderate or severe, strictly unilateral, stabbing 3 
or saw-tooth attacks lasting seconds to minutes. Attacks occur at least once a day 4 
and are associated with ipsilateral cranial autonomic symptoms or signs.[1] 5 
Incidence is 1.2/100,000, and around 58% will respond to medical therapy. When 6 
autonomic features include both conjunctival injection and lacrimation (tearing), the 7 
disorder is subclassified as short-lasting unilateral neuralgiform headache attacks 8 
with conjunctival injection and tearing (SUNCT). When autonomic symptoms include 9 
only one or neither of these ocular symptoms they are referred to as short-lasting 10 
unilateral neuralgiform headache attacks with cranial autonomic features (SUNA).[1] 11 
Functional neuroimaging studies in SUNHA and other trigeminal autonomic 12 
cephalalgias (TACs) have demonstrated involvement of the posterior hypothalamic 13 
region during attacks.[2] Moreover, as with trigeminal neuralgia (TN), a significant 14 
proportion of SUNHA patients display neurovascular conflict with the trigeminal 15 
nerve ipsilateral to the attacks.[3] This has led to the concept of a pathophysiological 16 
overlap between SUNHA, other TACs and TN.[4] 17 
Treatment options in medically refractory SUNHA patients are difficult to evaluate in 18 
a systematic fashion due to the severity and rarity of the condition combined with the 19 
paucity of reports in the literature. Over the last decade, peripheral and central 20 
neuromodulation as well as trigeminal microvascular decompression have emerged 21 
as efficacious treatments. [5-7] Reported outcomes after surgical interventions are 22 
currently limited to case reports or series. [5-8] Ablative interventions have been 23 
successfully used but have fallen out of favour because of their inconsistent results 24 
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and tendency to cause adverse effects, including possible anaesthesia 1 
dolorosa.[9,10][5,6] 2 
As with other TACs, peripheral neuromodulation has emerged as an option. Eight of 3 
nine patients receiving occipital nerve stimulation (ONS) for SUNHA were improved 4 
with four being rendered pain free.[5][7] Supraorbital and supratrochlear stimulation 5 
is limited to a single case report with reported benefit, albeit complicated by skin 6 
erosion and infection.[11][8] 7 
Central neuromodulation, purported to be posterior hypothalamic deep brain 8 
stimulation (DBS) and now understood to be in the ventral tegmental area (VTA), 9 
has provided substantial relief in three reported patients.[12-15][9-12] The 10 
experience from our centre is that 9 of 11 medically refractory SUNHA patients 11 
responded to DBS (defined as ≥ 50% reduction in headache frequency) with four 12 
patients rendered pain free (manuscript accepted for publication).[4] 13 
However, in a subset of patients with SUNHA and documented neurovascular 14 
conflict with the trigeminal nerve, 15 of 23 reported patients undergoing 15 
microvascular decompression (MVD) experienced complete resolution of pain.[7,16-16 
18][13-16] 17 
Here, we present two patients with medically refractory SUNCT who underwent MVD 18 
after a beneficial, but incomplete, response to neuromodulation. The aim of our 19 
report is to describe the response to MVD post neuromodulation in patients with 20 
medically intractable SUNCT to help practitioners consider the place for these 21 
surgical interventions in the treatment pathway. 22 
 23 
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CASE SERIES 1 
Patient 1 2 
An 80-year-old male presented with a 13-year history of SUNCT. Initially episodic, 3 
symptoms became chronic after the first 3-years. 4 
The SUNCT attacks were strictly right-sided, centred over the infra-orbital region with 5 
radiation to the forehead and the temple.  The attack frequency varied considerably, 6 
ranging from 10 to 100 daily. The attacks lasted 2-5 minutes and were excruciating 7 
in intensity. The attacks were accompanied by ipsilateral lacrimation, conjunctival 8 
injection, ptosis, rhinorrhoea, bilateral facial sweating and facial redness as well as 9 
nausea, photophobia and restlessness. Attacks were both spontaneous and 10 
triggered by eating and drinking, swallowing, talking, touching, wind and shaving. 11 
There was no refractory period. MRI confirmed ipsilateral arterial conflict with the 12 
trigeminal nerve (figure 1A). The patient failed to respond to numerous trials of 13 
preventive treatments, including a trial of indomethacin (table 1). 14 
ONS was implanted 7-years after symptom onset with a patient estimate of 80% 15 
improvement from baseline with reduction in severity, frequency and duration of 16 
attacks (previously reported in {Lambru:2014vx}). Over the years, SUNCT attacks 17 
gradually became more frequent and severe, although never reaching pre-ONS 18 
levels. Despite improvement from baseline, following ONS the patient still required 19 
an average of 1.2 hospital admissions and 4 outpatient consultations per year. A 20 
surgical opinion was again sought during an inpatient admission, when the patient 21 
had a severe exacerbation that proved difficult to manage with intravenous lidocaine. 22 
MVD was proposed and performed during the same admission. Branches of the 23 
superior cerebellar artery were found running between the fibres of the trigeminal 24 
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nerve and compressing the superior aspect of the nerve. Neural decompression was 1 
achieved by splitting the fascicles of the trigeminal nerve lengthwise, mobilising the 2 
offending vessels and placing Teflon felt between the offending arteries and nerve 3 
(Figure 1). Following the MVD, he became pain free immediately. Apart from 4 
temporal V2 numbness which has resolved, he remains pain and autonomic 5 
symptoms free 33-months following surgery. He stopped all medications for SUNCT 6 
and switched off the ONS device within a few weeks of MVD. He has not required 7 
hospital admission and attends ut-patient clinic once-a-year to ensure follow-up. 8 
Patient 2  9 
This 67-year-old gentleman presented with a 26-year history of right-sided SUNCT. 10 
Initially episodic, symptoms became chronic after the first 5-years. The attacks were 11 
strictly unilateral on right, centred on supra-orbital ridge and the temple. He had 50-12 
200 attacks daily, with each attack lasting between 10 seconds and 10 minutes. The 13 
pain was excruciating and accompanied by lacrimation, conjunctival injection, nasal 14 
blockage and rhinorrhoea. Attacks could be triggered by cutaneous touch, wind on 15 
the face, shouting, chewing and hair-combing. There was no refractory period. The 16 
combination of oxcarbazepine and lamotrigine was partially beneficial but the patient 17 
had significant side effects including unsteadiness, double vision, and tremor. He 18 
failed to respond to numerous other medications (see Table 1). MRI confirmed 19 
ipsilateral arterial conflict with the trigeminal nerve (Figure1C).  20 
21 years after symptoms started, VTA DBS was performed at age of 62 years. 21 
Following DBS, the patient reported an estimated 90% improvement in SUNCT 22 
symptoms with reduction in severity, frequency and duration of attacks (previously 23 
reported in {Miller:2016ix}. However, this was only achieved in combination with 24 
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continued oxcarbazepine and lamotrigine provoking side effects including 1 
unsteadiness, double vision and tremor. Multiple attempts to reduce medication 2 
caused significant SUNCT pain recurrence. Despite improvement following DBS, an 3 
average of 1.3 hospital admissions and 2 outpatient clinic consultations a year were 4 
required. After surgical review in our multidisciplinary facial pain clinic, MVD was 5 
proposed and performed. He became pain free immediately following surgery. 6 
Twenty-three-months after MVD surgery he remains pain free with no autonomic 7 
symptoms; there is a small area of reduced sensation to pinprick in V2 with corneal 8 
sensation intact. He no longer takes any medications for SUNCT and the DBS 9 
system has been switched off. He has not required hospital admission and attends 10 
out-patient clinic once-a-year to ensure follow-up. 11 
 12 
DISCUSSION 13 
Surgical treatment of medically intractable SUNHA is challenging because of the 14 
severity and rarity of the condition combined with the paucity of reports of effective 15 
treatments in the literature. Severe, medically intractable SUNHA is rare and there is 16 
a paucity of reports of effective surgical treatments in the literature. Ablative 17 
interventions have been successfully used but they have fallen out of favour because 18 
of their inconsistent results and tendency to cause adverse effects, including 19 
possible anaesthesia dolorosa. Over the last decade, neuromodulation and MVD 20 
have been reported as being efficacious but a head-to-head“within patient” 21 
comparison has not previously been reported available in the literature. 22 
Here we report on two patients with medically intractable SUNCT who obtained 23 
beneficial but incomplete response to peripheral or central neuromodulation with 24 
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ONS and DBS respectively. Repeat outpatient visits were required to optimise 1 
medical therapy and neuromodulation settings. However, both patients became pain 2 
free of SUNCT symptoms following trigeminal MVD. Both patients were able to stop 3 
medication and deactivate the neurostimulators. Moreover, there was no further 4 
need for hospital admission or numerous follow up appointments. One could argue 5 
that numbness following surgery points to ablation as the mechanism of action, 6 
However, the transient nature of this in one patient and the small area affected, 7 
outside the formerly painful area in the other patient, suggest that this is not the 8 
mechanism of action. Although the length of follow up is relatively short (23- and 33-9 
months) we are encouraged by extrapolation from the literature on MVD for TN 10 
where recurrence rates 10-years after successful MVD are remarkably low (around 11 
10-20%).[19][17] 12 
We hesitate to suggest “guidelines” for the management of medically refractory 13 
SUNA and SUNCT on such a small worldwide, and even smaller local, experience. 14 
HoweverB, based on the available evidence, we propose that all SUNA and SUNCT 15 
patients undergo high quality MR imaging of the prepontine cistern to rule out 16 
pathological processes in the region as well as to examine for neurovascular conflict.  17 
We now offer MVD as a first procedure to those patients with neurovascular conflict 18 
who remain symptomatic or suffer from significant side-effects despite optimal 19 
medical management. As with every neurosurgical procedure, MVD carries risks 20 
including cerebrospinal fluid leak, neurological deficit or death. Nevertheless, in 21 
experienced centres, the risk of serious harm is <1% and MVD in such patients is the 22 
closest that we can offer to a symptomatic “cure”. We reserve neuromodulation for 23 
patients without MRI evidence of trigeminal neurovascular conflict or for those with 24 
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conflict who have not responded to MVD. In these patients, we offer ONS, reserving 1 
DBS for when ONS is not available or has failed to provide sufficient benefit. 2 
 3 
CONCLUSION 4 
In patients with medically intractable SUNCT and evidence of neurovascular conflict 5 
on MR imaging, MVD may be considered before offering neuromodulation 6 
procedures. 7 
 8 
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Clinical Implications 4 
Microvascular decompression is a valid treatment option for SUNCT 5 
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Table 1. Medication History (NT, not tried; NK, not known) 
Drug 
Patient 1 Patient 2 
Daily Dose Effect Daily Dose Effect 
Lamotrigine  225mg Partially effective; severe 
confusion  
700mg Partially effective; marked drowsiness 
and poor memory 
Carbamazepine  NK Ineffective 800mg 
 
Partially effective; severe dizziness, 
double vision and tremor.  
Oxcarbazepine NT  600mg Partially effective; tremor, dizziness 
and unsteadiness. 
Topiramate 175mg Ineffective; cognitive slowing, 
nausea and weight loss  
400mg Ineffective. 
Gabapentin 4500mg Ineffective NK Ineffective 
Pregabalin 500mg Ineffective NT  
Baclofen NT  NK Ineffective 
Phenytoin NT  250mg ineffective 
Melatonin 12mg Ineffective 9mg Ineffective 
Lidocaine patches 5% patch for 12 
hours daily 
Mild benefit; confusion 5% patch for 12 
hours daily 
Ineffective 
Intravenous 
lidocaine 
1- 4mg/min for 
7 days 
No attacks during infusion with 
rapid recurrence when infusion 
discontinued; developed sinus 
tachycardia 
1- 4mg/min for 7 
days 
No attacks during infusion with rapid 
recurrence when infusion 
discontinued 
Greater occipital  Partially beneficial for 3 days  Ineffective 
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nerve block 
Amitriptyline NK Ineffective NT  
Lithium NK Ineffective NK ineffective 
Prednisolone NK Ineffective NT  
Indomethacin  150mg Ineffective 150mg Ineffective 
Subcutaneous 
Sumatriptan  
6mgs as 
needed 
Ineffective 6mgs as needed Ineffective 
High flow oxygen 100% at 12 
litres/min 
Ineffective NT  
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Figure 1 
Left column: Patient 1 with right sided SUNCT. A: High resolution axial CISS 1.5 
MRI sequences confirming neurovascular conflict with the right trigeminal nerve. B: 
Intraoperative microscope images: A leash of arterial vessels can be seen in 
conflict with the right trigeminal nerve in the first image. After retraction of the 
intervening petrosal vein, one of the offending arteries is clearly seen passing 
between the fascicles of the trigeminal nerve in the second image. After mobilisation 
of the offending vessels and splitting of the trigeminal fascicles, Teflon felt has been 
placed between the most superficial vessel and the surrounding trigeminal fibres in 
the third image. Further Teflon pieces were placed between the offending vessels 
and trigeminal nerve prior to surgical closure (not shown).  
Right column: Patient 2 with left-sided SUNCT. C: High resolution axial CISS 1.5 
MRI sequences confirming neurovascular conflict with the left trigeminal nerve. D: 
Intraoperative microscope photos: In the top image, thick arachnoid membranes 
can be seen matting a loop of the superior cerebellar artery to the superior and 
medial aspect of the left trigeminal nerve. After division of the arachnoid membranes 
and mobilisation of the offending vessel, the second image gives a clearer view of 
the underlying anatomy. The thin white band of the fourth cranial nerve can be seen 
coursing around the midbrain in the hiatus between petrosal vein and tentorium. The 
lowest image documents the bright white Teflon felt placed between offending vessel 
and trigeminal nerve. 
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Table 1. Medication History  
Drug 
Patient 1 Patient 2 
Daily Dose Effect Daily Dose Effect 
Lamotrigine  225mg Partially effective; severe confusion  700mg Partially effective; marked drowsiness 
and poor memory 
Carbamazepine  NK Ineffective 800mg Partially effective; severe dizziness, double vision and tremor.  
Oxcarbazepine NT  600mg Partially effective; tremor, dizziness and unsteadiness. 
Topiramate 175mg Ineffective; cognitive slowing, nausea and weight loss  400mg Ineffective. 
Gabapentin 4500mg Ineffective NK Ineffective 
Pregabalin 500mg Ineffective NT  
Baclofen NT  NK Ineffective 
Phenytoin NT  250mg ineffective 
Melatonin 12mg Ineffective 9mg Ineffective 
Lidocaine patches 5% patch for 12 hours daily Mild benefit; confusion 5% patch for 12 hours daily Ineffective 
Intravenous lidocaine 1- 4mg/min for 7 days No attacks during infusion with rapid recurrence when infusion 
discontinued; developed sinus tachycardia 
1- 4mg/min for 7 days No attacks during infusion with rapid recurrence when infusion 
discontinued 
Greater occipital nerve block  Partially beneficial for 3 days  Ineffective 
Amitriptyline NK Ineffective NT  
Lithium NK Ineffective NK ineffective 
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Page 2 
Prednisolone NK Ineffective NT  
Indomethacin  150mg Ineffective 150mg Ineffective 
Subcutaneous 
Sumatriptan  
6mgs as needed Ineffective 6mgs as needed Ineffective 
High flow oxygen 100% at 12 litres/min Ineffective NT  
 
NT, not tried; NK, not known
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Figure 1: Left column: Patient 1 with right sided SUNCT. A: High resolution axial CISS 1.5 MRI sequences 
confirming neurovascular conflict with the right trigeminal nerve. B:Intraoperative microscope images: A 
leash of arterial vessels can be seen in conflict with the right trigeminal nerve in the first image. After 
retraction of the intervening petrosal vein, one of the offending arteries is clearly seen passing between the 
fascicles of the trigeminal nerve in the second image. After mobilisation of the offending vessels and splitting 
of the trigeminal fascicles, Teflon felt has been placed between the most superficial vessel and the 
surrounding trigeminal fibres in the third image. Further Teflon pieces were placed between the offending 
vessels and trigeminal nerve prior to surgical closure (not shown).  
Right column: Patient 2 with left-sided SUNCT. C: High resolution axial CISS 1.5 MRI sequences confirming 
neurovascular conflict with the left trigeminal nerve. D:Intraoperative microscope photos: In the top image, 
thick arachnoid membranes can be seen matting a loop of the superior cerebellar artery to the superior and 
medial aspect of the left trigeminal nerve. After division of the arachnoid membranes and mobilisation of the 
offending vessel, the second image gives a clearer view of the underlying anatomy. The thin white band of 
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the fourth cranial nerve can be seen coursing around the midbrain in the hiatus between petrosal vein and 
tentorium. The lowest image documents the bright white Teflon felt placed between offending vessel and 
trigeminal nerve.  
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     CARE Checklist (2013) of information to include when writing a case report 
    
Topic Item  Checklist item description Reported on Page 
Title 1 The words “case report” should be in the title along with what is of greatest interest in this case . . . . . . . . . . . . . . . . 
. . . . . .  
1 
Key Words 2 The key elements of this case in 2 to 5 key words . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
. . . . . .  
3 
Abstract 3a Introduction—What is unique about this case? What does it add to the medical literature? . . . . . . . . . . . . . . . . . . . .  2 
3b The main symptoms of the patient and the important clinical findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   2 
3c The main diagnoses, therapeutics interventions, and outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 
3d Conclusion—What are the main “take-away” lessons from this case?  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  2 
Introduction 4 Brief background summary of this case referencing the relevant medical literature . . . . . . . . . . . . . . . . . . .   5-6 
Patient Information 5a Demographic information (such as age, gender, ethnicity, occupation) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7-8 
5b Main symptoms of the patient (his or her chief complaints)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7-8 
5c 
Medical, family, and psychosocial history including co-morbidities, and relevan t genetic information . 
.  7-8 
5d Relevant past interventions and their outcomes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   7-8 
Clinical Findings 6 Describe the relevant physical examination (PE) findings. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
Timeline 7 Depict important milestones related to your diagnoses and interventions (table or figure) . . . . . . . . . . . .  attched 
Diagnostic 
Assessment 
8a Diagnostic methods (such as PE, laboratory testing, imaging, questionnaires). . . . . . . . . . . . . . . . . . . . . . .  7-8, Figure1 
8b Diagnostic challenges (such as financial, language, or cultural) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
8c Diagnostic reasoning including other diagnoses considered . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
8d Prognostic characteristics (such as staging in oncology) where applicable . . . . . . . . . . . . . . . . . . . . . . . . . .   
Therapeutic 
Intervention 
9a Types of intervention (such as pharmacologic, surgical, preventive, self-care) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7-8 
9b Administration of intervention (such as dosage, strength, duration)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  Table 1 
9c Changes in intervention (with rationale)  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
Follow-up and 
Outcomes 
10a Clinician-assessed outcomes and when appropriate patient-assessed outcomes. . . . . . . . . . . . . . . . . . . . . . . . . . . .     
10b Important follow-up test results  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .         7-8 
10c Intervention adherence and tolerability (How was this assessed?) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .   
10d Adverse and unanticipated events  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  7-9 
Discussion 11a Discussion of the strengths and limitations in the management of this case . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  9-10 
11b Discussion of the relevant medical literature. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  9-10 
11c The rationale for conclusions (including assessment of possible causes) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  10 
11d The main “take-away” lessons of this case report . . . . . . . . . . . . . . . . . . . . . . . . . .  .. . . . . . . . . . . . . . . . . . . . . . . . . .  10 
Patient Perspective 12 Did the patient share his or her perspective or experience? (Include when appropriate)   . . . . . . . . . . . . . . . . . . . . . .    
Informed Consent 13 Did the patient give informed consent? Please provide if requested  . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .     Yes   
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Page 2 
 
ABSTRACT: 
Objectives: To assess the relative effectiveness of neuromodulation and trigeminal 
microvascular decompression in patients with medically intractable short-lasting unilateral 
neuralgiform headache attacks with conjunctival injection and tearing. 
Methods: Two patients with medically refractory short-lasting unilateral neuralgiform 
headache attacks with conjunctival injection and tearing underwent trigeminal microvascular 
decompression following beneficial but incomplete response to neuromodulation (occipital 
nerve stimulation and deep brain stimulation). MRI confirmed neurovascular conflict with 
the ipsilateral trigeminal nerve in both patients. 
Results: Although neuromodulation provided significant benefit, it did not deliver complete 
relief from pain. Conversely, trigeminal microvascular decompression was successful in 
eliminating symptoms in both patients with no need for further medical treatment or 
neuromodulation. 
Conclusion: Neuromodulation requires expensive hardware and lifelong follow up and 
maintenance. These case reports highlight that microvascular decompression may be 
preferable to neuromodulation in the subset of short-lasting unilateral neuralgiform headache 
attacks with conjunctival injection and tearing patients with ipsilateral neurovascular conflict.  
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List of all abbreviations used 
CISS   constructive interference in steady state 
DBS   deep brain stimulation 
ONS   occipital nerve stimulation 
MRI   magnetic resonance imaging   
MVD   microvascular decompression 
SUNA  short-lasting unilateral neuralgiform headache attacks with cranial autonomic 
features 
SUNCT  short-lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing 
SUNHA short-lasting unilateral neuralgiform headache attacks 
TACs   trigeminal autonomic cephalalgias 
TN   trigeminal neuralgia 
VTA   ventral tegmental area 
V2  2
nd
 division of trigeminal nerve 
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Page 5 
INTRODUCTION 
Short-lasting unilateral neuralgiform headache attacks (SUNHA) are a rare primary headache 
disorder characterised by moderate or severe, strictly unilateral, stabbing or saw-tooth attacks 
lasting seconds to minutes. Attacks occur at least once a day and are associated with 
ipsilateral cranial autonomic symptoms or signs.[1] Incidence is 1.2/100,000. When 
autonomic features include both conjunctival injection and lacrimation (tearing), the disorder 
is sub-classified as short-lasting unilateral neuralgiform headache attacks with conjunctival 
injection and tearing (SUNCT). When autonomic symptoms include only one or neither of 
these ocular symptoms they are referred to as short-lasting unilateral neuralgiform headache 
attacks with cranial autonomic features (SUNA).[1] 
Functional neuroimaging studies in SUNHA and other trigeminal autonomic cephalalgias 
(TACs) have demonstrated involvement of the posterior hypothalamic region during 
attacks.[2] Moreover, as with trigeminal neuralgia (TN), a significant proportion of SUNHA 
patients display neurovascular conflict with the trigeminal nerve ipsilateral to the attacks.[3] 
This has led to the concept of a pathophysiological overlap between SUNHA and TN.[4] 
A significant proportion of SUNHA patients fail to respond to medical treatments. Treatment 
options in these medically refractory patients are difficult to evaluate in a systematic fashion 
due to the severity and rarity of the condition combined with the paucity of reports in the 
literature. Over the last decade, peripheral and central neuromodulation as well as trigeminal 
microvascular decompression have emerged as efficacious treatments. Reported outcomes 
after surgical interventions are currently limited to case reports or series. Ablative 
interventions have been successfully used but have fallen out of favour because of their 
inconsistent results and tendency to cause adverse effects, including possible anaesthesia 
dolorosa.[5,6] 
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Page 6 
As with other TACs, peripheral neuromodulation has emerged as an option. Eight of nine 
patients receiving occipital nerve stimulation (ONS) for SUNHA were improved with four 
being rendered pain free.[7] Supraorbital and supratrochlear stimulation is limited to a single 
case report with reported benefit, albeit complicated by skin erosion and infection.[8] 
Central neuromodulation, purported to be posterior hypothalamic deep brain stimulation 
(DBS) and now understood to be in the ventral tegmental area (VTA), has provided 
substantial relief in three reported patients.[9-12] The experience from our centre is that 9 of 
11 medically refractory SUNHA patients responded to DBS (defined as ≥ 50% reduction in 
headache frequency) with four patients rendered pain free.[4,13] 
However, in a subset of patients with SUNHA and documented neurovascular conflict with 
the trigeminal nerve, 15 of 23 reported patients undergoing microvascular decompression 
(MVD) experienced complete resolution of pain.[14-17] 
Here, we present two patients with medically refractory SUNCT who underwent MVD after 
a beneficial, but incomplete, response to neuromodulation. The aim of our report is to 
describe the response to MVD post-neuromodulation in patients with medically intractable 
SUNCT to help practitioners consider the place for thes  surgical interventions in the 
treatment pathway. 
 
 
CASE SERIES 
Patient 1 
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An 80-year-old male presented with a 13-year history of SUNCT. Initially episodic, 
symptoms became chronic after the first 3-years. 
The SUNCT attacks were strictly right-sided, centred over the infra-orbital region with 
radiation to the forehead and the temple.  The attack frequency varied considerably, ranging 
from 10 to 100 daily. The attacks lasted 2-5 minutes and were excruciating in intensity. The 
attacks were accompanied by ipsilateral lacrimation, conjunctival injection, ptosis, 
rhinorrhoea, bilateral facial sweating and facial redness as well as nausea, photophobia and 
restlessness. Attacks were both spontaneous and triggered by eating and drinking, 
swallowing, talking, touching, wind and shaving. There was no refractory period. MRI 
confirmed ipsilateral arterial conflict with the trigeminal nerve (figure 1A). The patient failed 
to respond to numerous trials of preventive treatments (table 1). 
ONS was implanted 7-years after symptom onset with a patient estimate of 80% 
improvement from baseline. Over the years, SUNCT attacks gradually became more frequent 
and severe, although never reaching pre-ONS levels. Despite improvement from baseline, 
following ONS the patient still required an average of 1.2 hospital admissions and 4 
outpatient consultations per year. A surgical opinion was again sought during an inpatient 
admission, when the patient had a severe exacerbation that proved difficult to manage with 
intravenous lidocaine. MVD was proposed and performed during the same admission. 
Branches of the superior cerebellar artery were found running between the fibres of the 
trigeminal nerve and compressing the superior aspect of the nerve. Neural decompression 
was achieved by splitting the fascicles of the trigeminal nerve lengthwise, mobilising the 
offending vessels and placing Teflon felt between the offending arteries and nerve (Figure 1). 
Following the MVD, he became pain free immediately. Apart from temporal V2 numbness 
which has resolved, he remains free of pain and autonomic symptoms 33-months following 
surgery. He stopped all medications for SUNCT and switched off the ONS device within a 
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few weeks of MVD. He has not required hospital admission and attends out-patient clinic 
once-a-year to ensure follow-up. 
Patient 2  
This 67-year-old gentleman presented with a 26-year history of right-sided SUNCT. Initially 
episodic, symptoms became chronic after the first 5-years. The attacks were strictly unilateral 
on right, centred on the forehead and the temple. He had 50-200 attacks daily, with each 
attack lasting between 10 seconds and 10 minutes. The pain was excruciating and 
accompanied by lacrimation, conjunctival injection, nasal blockage and rhinorrhoea. Attacks 
could be triggered by cutaneous touch, wind on the face, shouting, chewing and hair-
combing. There was no refractory period. The combination of oxcarbazepine and lamotrigine 
was partially beneficial but the patient had significant side effects including unsteadiness, 
double vision, and tremor. He failed to respond to numerous other medications (see Table 1). 
MRI confirmed ipsilateral arterial conflict with the trigeminal nerve (Figure1C).  
Twenty-one years after the symptoms started, VTA DBS was performed at age of 62 years. 
Following DBS, the patient reported an estimated 90% improvement in SUNCT symptoms. 
However, this was only achieved in combination with continued oxcarbazepine and 
lamotrigine, which continued to cause the side effects outlined above. Multiple attempts to 
reduce medication caused marked worsening of the SUNCT attacks. Despite improvement 
following DBS, an average of 1.3 hospital admissions and 2 outpatient clinic consultations a 
year were required. After surgical review in our multidisciplinary facial pain clinic, MVD 
was proposed and performed. He became pain free immediately following surgery. Twenty-
three months after MVD surgery he remains pain free with no autonomic symptoms; there is 
a small area of reduced sensation to pinprick in V2 with corneal sensation intact. He no 
longer takes any medications for SUNCT and the DBS system has been switched off. He has 
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not required hospital admission and attends out-patient clinic once-a-year to ensure follow-
up. 
 
DISCUSSION 
Surgical treatment of medically intractable SUNHA is challenging because of the severity 
and rarity of the condition combined with the paucity of reports of effective treatments in the 
literature. Ablative interventions have been successfully used but they have fallen out of 
favour because of their inconsistent results and tendency to cause adverse effects, including 
possible anaesthesia dolorosa. Over the last decade, neuromodulation and MVD have been 
reported as being efficacious but a head-to-head comparison has not previously been reported 
in the literature. 
Here we report on two patients with medically intractable SUNCT who obtained beneficial 
but incomplete response to peripheral or central neuromodulation with ONS and DBS, 
respectively. Repeat outpatient visits were required to optimise medical therapy and 
neuromodulation settings. However, both patients became pain free following trigeminal 
MVD. Both patients could stop medications and deactivate the neurostimulators. Moreover, 
there was no further need for hospital admission or numerous follow up appointments. One 
could argue that numbness following surgery points to ablation as the mechanism of action, 
However, the transient nature of this in one patient and the small area affected, outside the 
formerly painful area in the other patient, suggest that this is not the mechanism of action. 
Although the length of follow up is relatively short (23- and 33-months) we are encouraged 
by extrapolation from the literature on MVD for TN where recurrence rates 10-years after 
successful MVD are remarkably low (around 10-20%).[18] 
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We hesitate to suggest “guidelines” for the management of medically refractory SUNA and 
SUNCT on such a small worldwide, and even smaller local, experience. However, based on 
the available evidence, we propose that all SUNA and SUNCT patients undergo high quality 
MR imaging of the prepontine cistern to rule out pathological processes in the region as well 
as to examine for neurovascular conflict.  
We now offer MVD as a first procedure to those patients with neurovascular conflict. As 
with every neurosurgical procedure, MVD carries risks including cerebrospinal fluid leak, 
neurological deficit or death. Nevertheless, in experienced centres, the risk of serious harm is 
<1% and MVD in such patients is the closest that we can offer to a symptomatic “cure”. We 
reserve neuromodulation for patients without MRI evidence of trigeminal neurovascular 
conflict or for those with conflict who have not responded to MVD. In these patients, we 
offer ONS, reserving DBS for when ONS is not available or has failed to provide sufficient 
benefit. 
 
CONCLUSION 
In patients with medically intractable SUNCT and evidence of neurovascular conflict on MR 
imaging, MVD may be considered before offering neuromodulation procedures. 
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Clinical Implications 
Microvascular decompression is a valid treatment option for short-lasting unilateral 
neuralgiform headache attacks with autonomic symptoms 
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Please inset figure 1 
Figure 1: Left column: Patient 1 with right sided SUNCT. A: High resolution axial CISS 1.5 
MRI sequences confirming neurovascular conflict with the right trigeminal nerve. 
B:Intraoperative microscope images: A leash of arterial vessels can be seen in conflict with 
the right trigeminal nerve in the first image. After retraction of the intervening petrosal vein, 
one of the offending arteries is clearly seen passing between the fascicles of the trigeminal 
nerve in the second image. After mobilisation of the offending vessels and splitting of the 
trigeminal fascicles, Teflon felt has been placed between the most superficial vessel and the 
surrounding trigeminal fibres in the third image. Further Teflon pieces were placed between 
the offending vessels and trigeminal nerve prior to surgical closure (not shown).  
Right column: Patient 2 with left-sided SUNCT. C: High resolution axial CISS 1.5 MRI 
sequences confirming neurovascular conflict with the left trigeminal nerve. D:Intraoperative 
microscope photos: In the top image, thick arachnoid membranes can be seen matting a loop 
of the superior cerebellar artery to the superior and medial aspect of the left trigeminal nerve. 
After division of the arachnoid membranes and mobilisation of the offending vessel, the 
second image gives a clearer view of the underlying anatomy. The thin white band of the 
fourth cranial nerve can be seen coursing around the midbrain in the hiatus between petrosal 
vein and tentorium. The lowest image documents the bright white Teflon felt placed between 
offending vessel and trigeminal nerve. 
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